NCT04477200 is a Phase 1 clinical trial of Mycophenolate Mofetil in Recurrent Glioblastoma, sponsored by University of Michigan Rogel Cancer Center.

Who is sponsoring NCT04477200?

NCT04477200 is sponsored by University of Michigan Rogel Cancer Center.

What drugs are being tested in NCT04477200?

Interventions in NCT04477200: Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide, Mycophenolate Mofetil, Mycophenolate Mofetil, Radiation Therapy.

What condition does NCT04477200 study?

NCT04477200 studies Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV.

Is NCT04477200 still recruiting?

NCT04477200 is currently active, enrolled. Last updated 29 June 2025.

Last reviewed 2025-06-29 · How we verify

NCT04477200

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Active, enrolled Phase 1 Last updated 29 June 2025

What this trial tests

Phase 1 trial testing Mycophenolate Mofetil in Recurrent Glioblastoma in 68 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 August 2020

Primary endpoint
6 January 2025

5 November 2027

Quick facts

Lead sponsor	University of Michigan Rogel Cancer Center
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	5 August 2020
Primary completion	6 January 2025
Estimated completion	5 November 2027
Sites	1 location across United States

Drugs / interventions tested

Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Radiation Therapy — full drug profile →
Re-resection (as part of standard of care)
Temozolomide (temozolomide) — full drug profile →
Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Radiation Therapy — full drug profile →

Conditions studied

Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
Recurrent Gliosarcoma — all drugs for Recurrent Gliosarcoma →
Recurrent Astrocytoma, Grade IV — all drugs for Recurrent Astrocytoma, Grade IV →
Newly Diagnosed Glioblastoma — all drugs for Newly Diagnosed Glioblastoma →

Sponsor

University of Michigan Rogel Cancer Center

Who can join

18 and older, any sex, with Recurrent Glioblastoma or Recurrent Gliosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nucleotide metabolism: a pan-cancer metabolic dependency.
Mullen NJ, Singh PK. · · 2023 · cited 308× · PMID 36973407 · DOI 10.1038/s41568-023-00557-7
Emerging roles of nucleotide metabolism in cancer.
Shi DD, Savani MR, Abdullah KG, McBrayer SK. · · 2023 · cited 57× · PMID 37173188 · DOI 10.1016/j.trecan.2023.04.008
GTP Signaling Links Metabolism, DNA Repair, and Responses to Genotoxic Stress.
Zhou W, Zhao Z, Lin A, Yang JZ, et al · · 2024 · cited 21× · PMID 37902550 · DOI 10.1158/2159-8290.cd-23-0437
Rewiring of cortical glucose metabolism fuels human brain cancer growth.
Scott AJ, Mittal A, Meghdadi B, O'Brien A, et al · · 2025 · cited 20× · PMID 40903569 · DOI 10.1038/s41586-025-09460-7
Metabolomic Profiles of Human Glioma Inform Patient Survival.
Scott AJ, Correa LO, Edwards DM, Sun Y, et al · · 2023 · cited 17× · PMID 36852494 · DOI 10.1089/ars.2022.0085
Factors affecting the radiation response in glioblastoma.
Aiyappa-Maudsley R, Chalmers AJ, Parsons JL. · · 2022 · cited 17× · PMID 36325371 · DOI 10.1093/noajnl/vdac156
Clinical Targeting of Altered Metabolism in High-Grade Glioma.
Scott AJ, Lyssiotis CA, Wahl DR. · · 2021 · cited 17× · PMID 34570453 · DOI 10.1097/ppo.0000000000000550
One-Carbon Metabolism Associated Vulnerabilities in Glioblastoma: A Review.
Ghannad-Zadeh K, Das S. · · 2021 · cited 17× · PMID 34205450 · DOI 10.3390/cancers13123067

Verify or expand the search:

Other trials of Mycophenolate Mofetil

Trials testing the same drug.

NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu · Phase 1 · not yet recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07524530 — Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers · Phase 2 · not yet recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other recruiting trials for Recurrent Glioblastoma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting

Other University of Michigan Rogel Cancer Center trials

Trials by the same sponsor.

NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04477200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
Last refreshed: 29 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04477200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing